How Long Does It Take for Zepbound to Work? A Week-by-Week Timeline

Written by Nataliia Bondarchuk. Updated November 2, 2026.

Zepbound starts working within days, but meaningful weight loss takes weeks and the full effect takes over a year. After an injection, tirzepatide reaches its peak level in the blood within one to three days, and a steady level after about four weekly doses. In a 2025 study, people on tirzepatide ate over 500 fewer calories at a test meal than people on placebo by week 3. On the scale, most people see a clear change within the first two to three months: in a large analysis of the main trial, about four in five adherent participants had lost at least 5% of their weight by week 12. By week 20, when most people reach their maintenance dose, average loss in the trial was about 12.8 kg on the higher doses against 2.7 kg on placebo. Weight continued to fall until about week 72, when people had lost an average of 15% to 21% depending on the dose. This guide gives the timeline week by week, what to expect at each dose, what it means if you are a slower responder, and how long the effects on sleep apnea and blood pressure take.

Tirzepatide is injected under the skin once a week. According to the Zepbound label, it reaches its highest level in the blood a median of 24 hours after an injection (range 8 to 72 hours), has a half-life of about five to six days, and reaches a steady level after four weeks of weekly injections. That is why some people notice reduced appetite within the first week, while the effect becomes more consistent after the first month. How tirzepatide acts on appetite and blood sugar is explained in how Zepbound works.

A 2025 study in Nature Medicine measured eating directly. In 114 adults, people on tirzepatide ate 534 fewer calories at a test lunch than people on placebo by week 3, and 686 fewer by week 6, and reported feeling fuller and having fewer cravings from week 3. That study started at 5 mg rather than the label's 2.5 mg starting dose, so appetite effects at 2.5 mg may be milder. Food choices that help during this phase are covered in best foods to eat on tirzepatide.

The first four weeks are at 2.5 mg, a starting dose meant to let your body adjust; the label states it is not a maintenance dose. The dose then rises by 2.5 mg every four weeks to 5 mg, 7.5 mg and beyond, as set out in tirzepatide dosage. In SURMOUNT-1, the main obesity trial, most participants reached their maintenance dose by week 20, when people on 10 mg or 15 mg had lost an average of 12.8 kg against 2.7 kg on placebo. A post hoc analysis presented in 2024 found that of 1,545 participants who took the drug as prescribed, 1,267, about four in five, had lost at least 5% of their weight by week 12.

These are averages from clinical trials with diet and exercise counselling; individual results vary widely. A more detailed week-by-week guide is in tirzepatide weight loss by week.

The slow escalation reduces gut side effects, which in the trials occurred mainly during the dose-increase period. Each step lasts at least four weeks, so reaching 15 mg takes at least 20 weeks. Some people stay longer on a step if side effects are troublesome, which can delay weight loss slightly but makes it easier to continue. How long side effects usually last at each step is set out in how long Mounjaro side effects last.

The trial's authors noted that by 72 weeks weight had reached a plateau on 5 mg and was close to a plateau on 10 mg and 15 mg. Among people who kept taking the drug, more than half on 10 mg and 15 mg lost at least 20% of their weight.

You may simply be a slower responder. In the same post hoc analysis, 278 of 1,545 adherent participants, about 18%, had lost less than 5% by week 12. By week 24, 70% of them had reached 5%, and by week 72, 90% had lost at least 5%, 59% at least 10% and 30% at least 15%; on average they reached 5% at about week 25. The Zepbound label does not set a rule for stopping if weight loss is slow, so a slow start is a reason to review your dose and habits with your prescriber, not necessarily to stop. Common reasons for a slow start are covered in why am I not losing weight on tirzepatide.

In the SURMOUNT-OSA trials in adults with obesity and moderate to severe obstructive sleep apnea, breathing interruptions during sleep fell by about 51% and 59% on tirzepatide by week 52, against about 3% on placebo, alongside weight loss of 18% to 20%. Blood pressure also fell: in SURMOUNT-1, systolic pressure dropped by 7.2 mm Hg on average against 1.0 on placebo. In people with type 2 diabetes in SURMOUNT-2, A1c fell by 2.1 percentage points at 72 weeks against 0.5 on placebo. The trials reported these changes at their end points rather than week by week, so the exact timing of each improvement is less well documented than weight loss.

In SURMOUNT-4, people who lost an average of 20.9% over 36 weeks were then randomly assigned to continue or switch to placebo. Over the next 52 weeks, those who continued lost a further 5.5%, while those on placebo regained 14.0%. Zepbound works for as long as you take it, as discussed in what happens when you stop tirzepatide. If cost is the barrier, the options, including the KwikPen covered in Zepbound KwikPen, are set out in is there a generic Zepbound.

Zepbound gets into your system within days and reduces appetite within the first few weeks, most people see 5% weight loss by about three months, and the full effect builds over a year or more, levelling off around 72 weeks at an average of 15% to 21% depending on the dose. Slower starters often catch up. Results depend on staying on treatment, and weight tends to return after stopping. How tirzepatide compares with semaglutide on speed and size of weight loss is in tirzepatide vs semaglutide.

This article summarizes the Zepbound label and published trials for general information. Individual results vary; discuss your progress with your prescriber.